WO2005020862A8 - Crosslinking reagent for treating vertebral disc disorders - Google Patents

Crosslinking reagent for treating vertebral disc disorders

Info

Publication number
WO2005020862A8
WO2005020862A8 PCT/US2004/028039 US2004028039W WO2005020862A8 WO 2005020862 A8 WO2005020862 A8 WO 2005020862A8 US 2004028039 W US2004028039 W US 2004028039W WO 2005020862 A8 WO2005020862 A8 WO 2005020862A8
Authority
WO
WIPO (PCT)
Prior art keywords
increasing
intervertebral disc
tissue
crosslinking reagent
crosslinking
Prior art date
Application number
PCT/US2004/028039
Other languages
French (fr)
Other versions
WO2005020862A1 (en
Inventor
Thomas P Hedman
Original Assignee
Univ Southern California
Thomas P Hedman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/230,671 external-priority patent/US9084772B2/en
Priority claimed from US10/786,861 external-priority patent/US7435722B2/en
Application filed by Univ Southern California, Thomas P Hedman filed Critical Univ Southern California
Priority to CA2536415A priority Critical patent/CA2536415C/en
Priority to JP2006524909A priority patent/JP4955388B2/en
Priority to AU2004268628A priority patent/AU2004268628B2/en
Priority to EP04782506.2A priority patent/EP1660001B1/en
Priority to KR1020067004202A priority patent/KR101238647B1/en
Publication of WO2005020862A1 publication Critical patent/WO2005020862A1/en
Publication of WO2005020862A8 publication Critical patent/WO2005020862A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

A method of improving the resistance of collagenous tissue to mechanical degradation in accordance with the present invention comprises the step of contacting at least a portion of a collagenous tissue with an effective amount of a crosslinking reagent. Methods and devices for enhancing the body's own efforts to stabilize discs in scoliotic spines by increasing collagen crosslinks. This stability enhancement is caused by reducing the bending hysteresis and increasing the bending stiffness of scoliotic spines, by injecting non-toxic crosslinking reagents into the convex side of discs involved in the scoliotic curve. Alternatively, contact between the tissue and the crosslinking reagent is effected by placement of a time­-release delivery system directly into or onto the target tissue. Methods and devices that use crosslinking agents for increasing the permeability of an intervertebral disc, improving fluid flux to the intervertebral disc, and increasing the biological viability of cells within the intervertebral disc are provided.
PCT/US2004/028039 2001-08-31 2004-08-27 Crosslinking reagent for treating vertebral disc disorders WO2005020862A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2536415A CA2536415C (en) 2001-08-31 2004-08-27 Crosslinking reagent for treating intervertebral disc disorders
JP2006524909A JP4955388B2 (en) 2001-08-31 2004-08-27 Cross-linking reagent for treating spinal disc disease
AU2004268628A AU2004268628B2 (en) 2001-08-31 2004-08-27 Crosslinking reagents for treating intervertebral disc disorders
EP04782506.2A EP1660001B1 (en) 2001-08-31 2004-08-27 Crosslinking reagent for treating vertebral disc disorders
KR1020067004202A KR101238647B1 (en) 2003-08-28 2004-08-27 Crosslinking reagents for treating intervertebral disc disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31628701P 2001-08-31 2001-08-31
US10/230,671 US9084772B2 (en) 2001-08-31 2002-08-29 Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
US49879003P 2003-08-28 2003-08-28
US60/498,790 2003-08-28
US10/786,861 US7435722B2 (en) 2001-08-31 2004-02-24 Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
US10/786,861 2004-02-24

Publications (2)

Publication Number Publication Date
WO2005020862A1 WO2005020862A1 (en) 2005-03-10
WO2005020862A8 true WO2005020862A8 (en) 2005-05-19

Family

ID=46205331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/028039 WO2005020862A1 (en) 2001-08-31 2004-08-27 Crosslinking reagent for treating vertebral disc disorders

Country Status (7)

Country Link
US (1) US8450276B2 (en)
EP (1) EP1660001B1 (en)
JP (1) JP4955388B2 (en)
AU (1) AU2004268628B2 (en)
CA (1) CA2536415C (en)
TW (1) TW200526203A (en)
WO (1) WO2005020862A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006095A1 (en) 2010-06-28 2012-01-12 Hedman Thomas P Tissue crosslinking for treatment of snoring and obstructive sleep apnea
US8119599B2 (en) * 2001-08-31 2012-02-21 Orthopeutics, L.P. Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
US20070202143A1 (en) * 2001-08-31 2007-08-30 Hedman Thomas P Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints
EP1993497A4 (en) * 2006-02-02 2011-11-09 Tom Hedman Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity
US10278947B2 (en) 2007-02-28 2019-05-07 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
SE1550338A1 (en) * 2015-03-20 2016-09-21 Stayble Therapeutics Ab A composition for use in the treatment of intervertebral misalignment
WO2019151444A1 (en) * 2018-01-31 2019-08-08 国立大学法人神戸大学 Therapeutic agent for intervertebral disc degeneration and material for culturing intervertebral disc cells
CN113545337B (en) * 2021-07-21 2022-08-26 益诺思生物技术南通有限公司 Method for sizing a mammalian heart valve

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108438A (en) * 1989-03-02 1992-04-28 Regen Corporation Prosthetic intervertebral disc
US5270446A (en) 1989-04-04 1993-12-14 Suntory Limited Decolorized crosslinked products and method for decolorization of crosslinked products
FR2692582B1 (en) * 1992-06-18 1998-09-18 Flamel Tech Sa NEW CROSSLINKABLE DERIVATIVES OF COLLAGEN, THEIR PROCESS FOR OBTAINING IT AND THEIR APPLICATION TO THE PREPARATION OF BIOMATERIALS.
JPH0725761A (en) * 1993-07-09 1995-01-27 Kureha Chem Ind Co Ltd Agent for protecting cartilage
EP0713707A1 (en) * 1994-11-23 1996-05-29 Collagen Corporation In situ crosslinkable, injectable collagen composition for tissue augmention
US5865849A (en) * 1995-06-07 1999-02-02 Crosscart, Inc. Meniscal heterografts
US5916573A (en) * 1995-08-21 1999-06-29 Spiers; Samantha M. Topical treatment of the skin with a grapeseed oil composition
DE69720243T2 (en) 1996-11-05 2004-02-12 Challenge Bioproducts Co., Ltd. CHEMICAL MODIFICATION OF BIOMEDICAL MATERIALS WITH GENIPIN
WO1998055533A1 (en) 1997-06-04 1998-12-10 Biocompatibles Limited Zwitterionic compounds and their use to cross-link collagenous materials
US6080579A (en) * 1997-11-26 2000-06-27 Charlotte-Mecklenburg Hospital Authority Method for producing human intervertebral disc cells
US20010006948A1 (en) * 1998-11-25 2001-07-05 James D. Kang Gene transfer to intervertebral disc cells
US6534086B1 (en) * 2000-03-06 2003-03-18 Metagenics, Inc. Composition and method for treatment of inflammation and pain in mammals
US6428576B1 (en) * 1999-04-16 2002-08-06 Endospine, Ltd. System for repairing inter-vertebral discs
US6719797B1 (en) * 1999-08-13 2004-04-13 Bret A. Ferree Nucleus augmentation with in situ formed hydrogels
US9314339B2 (en) * 2000-03-27 2016-04-19 Formae, Inc. Implants for replacing cartilage, with negatively-charged hydrogel surfaces and flexible matrix reinforcement
US6723335B1 (en) * 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
US6620798B1 (en) 2000-06-06 2003-09-16 Russell Jaffe Synergistic agents for enhancing tissue repair
US6439238B1 (en) * 2000-06-30 2002-08-27 Pi Medical, Inc. Snoring diagnostic and treatment
WO2003002003A2 (en) * 2001-06-29 2003-01-09 The Trustees Of Columbia University Optical transesophageal echocardiography probe
US7435722B2 (en) * 2001-08-31 2008-10-14 University Of Southern California Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
US8119599B2 (en) * 2001-08-31 2012-02-21 Orthopeutics, L.P. Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
JP2005501874A (en) 2001-08-31 2005-01-20 ユニバーシティ・オブ・サザン・カリフォルニア Use of non-toxic cross-linking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral discs and other collagenous tissues
US8153600B2 (en) * 2001-08-31 2012-04-10 Orthopeutics, L.P. Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity
US8022101B2 (en) * 2001-08-31 2011-09-20 Orthopeutics, L.P. Method of treating a knee meniscus with a cross-linking reagent to increase resistance to tearing or rupturing
MXPA04005707A (en) * 2001-12-10 2005-06-20 Colbar Lifescience Ltd D Methods, devices, and preparations for intervertebral disc treatment.
US6812211B2 (en) * 2002-03-19 2004-11-02 Michael Andrew Slivka Method for nonsurgical treatment of the intervertebral disc and kit therefor
US7208171B2 (en) * 2002-10-31 2007-04-24 Northwestern University Injectable and bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation
US7157428B2 (en) * 2003-11-26 2007-01-02 Histogenics, Corp. Method for treatment and repair of meniscal injuries
US20100040593A1 (en) * 2008-08-15 2010-02-18 Orthopeutics, Lp Formulations for nonsurgical exogenous crosslink therapy
US8198248B2 (en) * 2008-08-15 2012-06-12 Orthopeutics, Lp Formulations for nonsurgical exogenous crosslink therapy
US8283322B2 (en) * 2008-08-15 2012-10-09 Orthopeutics, Lp Formulations for nonsurgical exogenous crosslink therapy

Also Published As

Publication number Publication date
TW200526203A (en) 2005-08-16
JP2007504162A (en) 2007-03-01
CA2536415A1 (en) 2005-03-10
WO2005020862A1 (en) 2005-03-10
US8450276B2 (en) 2013-05-28
AU2004268628A1 (en) 2005-03-10
AU2004268628B2 (en) 2009-11-12
EP1660001A4 (en) 2010-12-15
EP1660001A1 (en) 2006-05-31
EP1660001B1 (en) 2019-10-09
US20100266544A1 (en) 2010-10-21
CA2536415C (en) 2013-07-23
JP4955388B2 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
EP1521083A3 (en) Method for diagnosing and distinguishing stroke
WO2003027248A8 (en) Antibody inhibitors of gdf-8 and uses thereof
CA2437575A1 (en) Method and device for treating abnormal curvature of the spine
WO2005011522A3 (en) Prosthetic spinal disc replacement
WO2001036977A8 (en) Identification of disease markers involving mass-based-separation
WO2002102277A3 (en) Prosthetic graft assembly and method of use
WO2005020862A8 (en) Crosslinking reagent for treating vertebral disc disorders
WO2000043032A3 (en) Baff, inhibitors thereof and their use in the modulation of b-cell response
CY1107640T1 (en) METHOD FOR CERTIFICATING FACTORS FOR DIABETES TREATMENT
WO2004026161A3 (en) Low profile instrument immobilizer
WO2007089233A8 (en) Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity
WO1999049038A3 (en) Human calcium-binding proteins
WO2005054808A3 (en) Method for sex biasing spermatozoa
WO2006002016A3 (en) Medical systems for the spine and related methods
WO2003008553A3 (en) Proteins associated with cell growth, differentiation, and death
WO2000044900A3 (en) Nucleic-acid binding proteins
WO2003014322A3 (en) Proteins associated with cell growth, differentiation, and death
WO2003000844A3 (en) Protein modification and maintenance molecules
GB9312315D0 (en) Leukocyte adhesion assay
WO1999031128A3 (en) Human tumor necrosis factor-r2-like proteins
WO2000020604A3 (en) Oxidoreductase molecules
ATE452906T1 (en) THERAPEUTIC SUMMARY AND METHODS FOR MODULATING V3, AN ISOFORM OF VERSICAN
WO1999041373A3 (en) Human transport-associated molecules
WO2001083754A3 (en) Cellular regulators of infectious agents and methods of use
WO2001083524A3 (en) Rna metabolism proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

ENP Entry into the national phase

Ref document number: 2536415

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004782506

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067004202

Country of ref document: KR

Ref document number: 2006524909

Country of ref document: JP

Ref document number: 2004268628

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004268628

Country of ref document: AU

Date of ref document: 20040827

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004268628

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004782506

Country of ref document: EP